King Levoxyl
Executive Summary
Company will highlight May 25 NDA approval in marketing of its levothyroxine product. King projects second quarter sales of over $20 mil., up from $17.3 mil. in the first quarter. Levoxyl is the second approved levothyroxine product after Watson/Jerome Stevens's Unithroid. Abbott plans to file an NDA for its market leader Synthroid before FDA's Aug. 14 deadline (1"The Pink Sheet" May 7, p. 21)